drugset / Trial / NCT05527912
A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy
NaSequentialOpen-labelTreatment
Summary
This phase II trial studies how well giving rituximab,chidamide, and zanubrutinib with Sequential chemotherapy works in treating patients with double express diffuse large B-cell lymphoma. The prognosis of patients with DEL-DLBCL is usually worse than that of ordinary DLBCL.
Timeline
- Start
- 2023-02-24
- Primary completion
- 2024-09-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Subject | Pirarubicin | Small molecule | 50 mg/m2 | — |
| Subject | Prednisone | Other / unclassified | 30 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | — |